Tags : LentiVector

Juno Therapeutics Signs License and Clinical Supply Agreement with Oxford

Shots: Oxford Biomedica to receive $10M up front in cash, ~$86M as development and regulatory milestones, ~ $131M as commercial milestones and royalties on sales of products developed by Juno Therapeutics utilizing the LentiVector platform Oxford Biomedica will also receive payments from process development and scale-up projects as well as relating to the GMP manufacture […]Read More